Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222824
Real-world population study of patients with RA provides reassuring data regarding the risks of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) in patients initiating a JAKinib versus adalimumab, including patients at high risk of cardiovascular diseases.
Despite recent raised concerns of MACEs and VTEs among patients with RA receiving JAKinibs, observational studies among unselected populations outside of North America are still needed to assess JAKinib agents. To this end, Hoisnard, et al. undertook a nationwide population-based cohort study of the French national health data system, to compare the risk of MACEs and VTEs for patients initiating tofacitinib and baricitinib and those initiating adalimumab.